• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

维奈托克联合去甲基化药物治疗初治B/髓系混合表型急性白血病

Venetoclax Combined with Hypomethylating Agents for Treatment-Naïve B/Myeloid Mixed Phenotype Acute Leukemia.

作者信息

Wu Di, Chen Wenlan, Chen Zhichao, Li Qiubai

机构信息

Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei, China.

出版信息

Case Rep Hematol. 2021 Jan 12;2021:6661109. doi: 10.1155/2021/6661109. eCollection 2021.

DOI:10.1155/2021/6661109
PMID:33505737
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7815380/
Abstract

Mixed phenotype acute leukemia (MPAL) is a rare hematological malignancy that lacks consensus on optimal management. We report for the first time two cases of treatment-naïve B/myeloid MPAL patients treated with a novel chemo-free regimen using venetoclax combined with hypomethylating agents, which successfully induced complete remission with tolerable toxicities.

摘要

混合表型急性白血病（MPAL）是一种罕见的血液系统恶性肿瘤，在最佳治疗方案上缺乏共识。我们首次报告了两例未经治疗的B/髓系MPAL患者，采用一种新的无化疗方案，即维奈克拉联合去甲基化药物进行治疗，该方案成功诱导了完全缓解，且毒性可耐受。

相似文献

1
Venetoclax Combined with Hypomethylating Agents for Treatment-Naïve B/Myeloid Mixed Phenotype Acute Leukemia.维奈托克联合去甲基化药物治疗初治B/髓系混合表型急性白血病
Case Rep Hematol. 2021 Jan 12;2021:6661109. doi: 10.1155/2021/6661109. eCollection 2021.
2
Venetoclax and Decitabine for T/Myeloid Mixed-Phenotype Acute Leukemia Not Otherwise Specified (MPAL NOS).维奈托克与地西他滨用于治疗未另行指定的T/髓系混合表型急性白血病（MPAL NOS）。
Case Rep Hematol. 2020 Oct 10;2020:8811673. doi: 10.1155/2020/8811673. eCollection 2020.
3
Successful treatment of a B/T MPAL patient by chemo-free treatment with venetoclax, azacitidine, and blinatumomab.成功采用维奈托克、阿扎胞苷和blinatumomab 无化疗方案治疗 B/T 混合表型急性白血病患者。
Ann Hematol. 2024 Apr;103(4):1397-1402. doi: 10.1007/s00277-024-05644-9. Epub 2024 Feb 17.
4
First reported case of secondary mixed phenotype acute leukemia after multiple myeloma.首例多发性骨髓瘤后继发性混合表型急性白血病病例。
Am J Blood Res. 2021 Feb 20;11(1):123-131. eCollection 2021.
5
Multilineage Lymphoblastic Lymphoma as an Initial Presentation of Mixed Phenotype Acute Leukemia.多谱系淋巴细胞淋巴瘤作为混合表型急性白血病的初始表现
Case Rep Hematol. 2023 Feb 25;2023:3628712. doi: 10.1155/2023/3628712. eCollection 2023.
6
[Clinical Characteristics of Patients with Ph Mixed Phenotype Acute Leukemia].[Ph混合表型急性白血病患者的临床特征]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Apr;27(2):354-359. doi: 10.19746/j.cnki.issn.1009-2137.2019.02.007.
7
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.在未经治疗的老年急性髓系白血病患者中，venetoclax 联合地西他滨或阿扎胞苷的安全性和初步疗效：一项非随机、开放标签、1b 期研究。
Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.
8
T/myeloid mixed-phenotype acute leukemia treated with venetoclax and decitabine: A case report.采用维奈克拉和地西他滨治疗的T/髓系混合表型急性白血病：一例报告
World J Clin Cases. 2023 Sep 16;11(26):6200-6205. doi: 10.12998/wjcc.v11.i26.6200.
9
Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.在小剂量阿糖胞苷与阿柔比星联合粒细胞集落刺激因子（CAG方案）中增加阿柔比星剂量，作为复发/难治性混合表型急性白血病的挽救化疗是有效的。
Leuk Res. 2015 Aug;39(8):805-11. doi: 10.1016/j.leukres.2015.04.006. Epub 2015 Apr 20.
10
Acute lymphoblastic leukemia-like treatment regimen provides better response in mixed phenotype acute leukemia: a comparative study between adults and pediatric MPAL patients.急性淋巴细胞白血病样治疗方案在混合表型急性白血病中提供更好的反应：成人和儿科混合表型急性白血病患者的比较研究。
Ann Hematol. 2021 Mar;100(3):699-707. doi: 10.1007/s00277-020-04354-2. Epub 2020 Nov 23.

引用本文的文献

1
Chemotherapy-free treatment of B-lymphoid/myeloid mixed phenotype acute leukemia: two case reports and literature review.B淋巴细胞/髓系混合表型急性白血病的无化疗治疗：两例报告及文献综述
Immunotherapy. 2025 Jun;17(9):639-647. doi: 10.1080/1750743X.2025.2527018. Epub 2025 Jul 13.
2
[Efficacy and safety analysis of venetoclax in combination with multidrug chemotherapy in patients with newly diagnosed acute leukemia of ambiguous lineage].维奈托克联合多药化疗治疗新诊断的谱系不明急性白血病患者的疗效和安全性分析
Zhonghua Xue Ye Xue Za Zhi. 2025 Feb 14;46(2):161-168. doi: 10.3760/cma.j.cn121090-20240419-00149.
3
[Blinatumomab-based combination treatment for CD19-positive acute leukemia of an ambiguous lineage].[基于博纳吐单抗的混合治疗用于谱系不明的CD19阳性急性白血病]
Zhonghua Xue Ye Xue Za Zhi. 2024 Nov 14;45(11):1051-1054. doi: 10.3760/cma.j.cn121090-20240411-00133.
4
A hybrid protocol CLAG-M, a possible player for the first-line therapy of patients with mixed phenotype acute leukemia. A Polish Adult Leukemia Group experience.一种混合方案CLAG-M，可能是混合表型急性白血病患者一线治疗的选择。波兰成人白血病组的经验。
Front Oncol. 2024 May 21;14:1395992. doi: 10.3389/fonc.2024.1395992. eCollection 2024.
5
Venetoclax Combination Treatment of Acute Myeloid Leukemia in Adolescents and Young Adult Patients.维奈克拉联合治疗青少年和年轻成人急性髓系白血病
J Clin Med. 2024 Apr 1;13(7):2046. doi: 10.3390/jcm13072046.
6
Multilineage Lymphoblastic Lymphoma as an Initial Presentation of Mixed Phenotype Acute Leukemia.多谱系淋巴细胞淋巴瘤作为混合表型急性白血病的初始表现
Case Rep Hematol. 2023 Feb 25;2023:3628712. doi: 10.1155/2023/3628712. eCollection 2023.
7
Mixed-Phenotype Acute Leukemia: Clinical Diagnosis and Therapeutic Strategies.混合表型急性白血病：临床诊断与治疗策略
Biomedicines. 2022 Aug 15;10(8):1974. doi: 10.3390/biomedicines10081974.
8
Gilteritinib Combined with Azacitidine as Salvage Therapy for B/Myeloid Mixed Phenotype Acute Leukemia.吉瑞替尼联合阿扎胞苷作为B/髓系混合表型急性白血病的挽救治疗
Cureus. 2022 Mar 29;14(3):e23618. doi: 10.7759/cureus.23618. eCollection 2022 Mar.
9
Mixed Phenotype/Lineage Leukemia: Has Anything Changed for 2021 on Diagnosis, Classification, and Treatment?混合表型/谱系白血病：2021 年在诊断、分类和治疗方面有何变化？
Curr Oncol Rep. 2022 Aug;24(8):1015-1022. doi: 10.1007/s11912-022-01252-w. Epub 2022 Apr 5.
10
Pediatric Mixed-Phenotype Acute Leukemia: What's New?儿童混合表型急性白血病：有哪些新进展？
Cancers (Basel). 2021 Sep 16;13(18):4658. doi: 10.3390/cancers13184658.

本文引用的文献

1
Venetoclax and Decitabine for T/Myeloid Mixed-Phenotype Acute Leukemia Not Otherwise Specified (MPAL NOS).维奈托克与地西他滨用于治疗未另行指定的T/髓系混合表型急性白血病（MPAL NOS）。
Case Rep Hematol. 2020 Oct 10;2020:8811673. doi: 10.1155/2020/8811673. eCollection 2020.
2
Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia.维奈托克联合阿扎胞苷治疗难治性急性髓系白血病和混合表型急性白血病后行单倍体相合移植的疗效
Br J Haematol. 2020 Jun;189(5):e200-e204. doi: 10.1111/bjh.16622. Epub 2020 Apr 3.
3
Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: A case report and review of literature.维奈托克联合地西他滨治疗复发 T 细胞急性淋巴细胞白血病：病例报告及文献复习。
Hematol Oncol Stem Cell Ther. 2021 Sep;14(3):246-251. doi: 10.1016/j.hemonc.2019.10.002. Epub 2020 Mar 19.
4
Optimal therapeutic strategies for mixed phenotype acute leukemia.混合表型急性白血病的最佳治疗策略。
Curr Opin Hematol. 2020 Mar;27(2):95-102. doi: 10.1097/MOH.0000000000000570.
5
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.急性髓细胞白血病，第 3.2019 版，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2019 Jun 1;17(6):721-749. doi: 10.6004/jnccn.2019.0028.
6
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.维奈托克联合地西他滨或阿扎胞苷治疗初治老年急性髓系白血病患者。
Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25.
7
Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant.维奈托克联合地西他滨用于异基因造血细胞移植后复发的T细胞急性淋巴细胞白血病
Case Rep Hematol. 2018 Aug 26;2018:6092646. doi: 10.1155/2018/6092646. eCollection 2018.
8
The rise of apoptosis: targeting apoptosis in hematologic malignancies.细胞凋亡的兴起：血液系统恶性肿瘤中细胞凋亡的靶向治疗。
Blood. 2018 Sep 20;132(12):1248-1264. doi: 10.1182/blood-2018-02-791350. Epub 2018 Jul 16.
9
Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes.成人混合表型急性白血病的综合基因组分析描绘了与谱系相关的分子亚型。
Nat Commun. 2018 Jul 10;9(1):2670. doi: 10.1038/s41467-018-04924-z.
10
Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis.混合表型急性白血病患儿和成人的治疗：系统评价和荟萃分析。
Leukemia. 2018 Jul;32(7):1515-1528. doi: 10.1038/s41375-018-0058-4. Epub 2018 Feb 27.